MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNPR Stock Price Chart Interactive Chart >
MNPR Price/Volume Stats
|Current price||$2.25||52-week high||$6.98|
|Prev. close||$2.25||52-week low||$1.70|
|Day high||$2.25||Avg. volume||10,119|
|50-day MA||$2.39||Dividend yield||N/A|
|200-day MA||$3.66||Market Cap||28.40M|
MONOPAR THERAPEUTICS (MNPR) Company Bio
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Most Popular Stories View All
MNPR Latest News Stream
|Loading, please wait...|
MNPR Latest Social Stream
View Full MNPR Social Stream
Latest MNPR News From Around the Web
Below are the latest news stories about Monopar Therapeutics that investors may wish to consider to help them evaluate MNPR as an investment opportunity.
With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!
Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Pacira Pharmaceuticals (PCRX) and Monopar Therapeutics Inc (MNPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Pacira Pharmaceuticals (PCRX – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report). Masimo (MASI) BTIG analyst Marie Thibault maintained a Hold rating on Masimo today. The company's shares closed last Tuesday at $228.84. According to TipRanks.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced program updates across its pipeline and anticipated 2022
Maxim Group analyst Jason McCarthy maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) on February 2 and set a price target of $8.00. The company's shares closed last Friday at $2.76, close to its 52-week low of $2.36. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $16.67.
MNPR Price Returns